Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR3 | P49682 | 3/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | POLQ | O75417 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | HRH1 | P35367 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14373370 | 0.93 | NPC1 (0.63) | CXCR3NPC1RAB9AKDM4EKMT2A | |
| SCHEMBL14373371 | 0.87 | CXCR3 (0.66) | CXCR3NPC1RAB9AKDM4EKMT2A | |
| SCHEMBL14373372 | 0.87 | CXCR3 (0.74) | CXCR3KMT2AMEN1MAPT | |
| SCHEMBL14373373 | 0.84 | CXCR3 (0.58) | CXCR3NPC1RAB9AKMT2AMEN1 | |
| SCHEMBL14373252 | 0.76 | CXCR3 (0.70) | CXCR3NPC1RAB9AKMT2AMEN1 | |
| SCHEMBL5418563 | 0.76 | TSPO (0.65) | — | |
| SCHEMBL14373374 | 0.76 | CXCR3 (0.85) | CXCR3HTTNPC1RAB9AALDH1A1 | |
| SCHEMBL5452572 | 0.75 | F2R (0.53) | HTTLMNAMAPT | |
| SCHEMBL9887 | 0.74 | KMT2A (0.56) | NPC1RAB9AALDH1A1KDM4EKMT2A | |
| SCHEMBL4100208 | 0.72 | KDM4E (0.70) | CXCR3HTTNPC1RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1983992-A2 | 2-IMINO-BENZIMIDAZOLES | Abbott Laboratories (US) | 2008-10-29 | — | — | EP | disclosed |
| US-20070232673-A1 | 2-Imino-benzimidazoles | ABBOTT LABORATORIES | 2007-10-04 | — | — | US | disclosed |
| US-20070232673-A1 | 2-Imino-benzimidazoles | ABBOTT LABORATORIES | 2007-10-04 | — | — | US | disclosed |
| US-20070232673-A1 | 2-Imino-benzimidazoles | ABBOTT LABORATORIES | 2007-10-04 | — | — | US | disclosed |
| WO-2007084728-A2 | 2-IMINO-BENZIMIDAZOLES | ABBOTT LABORATORIES (US) | 2007-07-26 | — | — | WO | disclosed |
| WO-2007084728-A2 | 2-IMINO-BENZIMIDAZOLES | ABBOTT LABORATORIES (US) | 2007-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232673-A1 | 2-Imino-benzimidazoles | CYP2C19, UGT2B7, UGT2B17 | CXCR3 4743/4885HTT 4363/4885NPC1 234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.